Firm projects Lumigan product sales will total $490–$510 million in 2010.
FDA has approved Allergan’s Lumigan® 0.01% bimatoprost solution as first-line therapy for reducing intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The once-daily eye-drop product is an optimized reformulation of Lumigan 0.03%. Allergan says the drug will be available during the fourth quarter of 2010.
A three-month study with Lumigan 0.01% showed that treatment lowered IOP up to 7 mmHg from baseline in patients with an average baseline of 23.5 mmHg, despite using only one-third of the drug concentration in Lumigan 0.03%.
Allergan’s eyecare pharmaceuticals portfolio made net sales of $2.1 billion in the year to December 31 2010, up about $100,000 on sales in 2008. During May 2010 the firm reported FDA approval of Zymaxid™ 0.5%, a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis. The firm projects to achieve Lumigan franchise product net sales of $490-$510 million in 2010.
